Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: Potent and orally active antagonists of corticotropin-releasing factor 1 receptor

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5255-5269

  Takahashi, Yoshinori ^a   Hibi, Shigeki ^a   Hoshino, Yorihisa ^a   Kikuchi, Koichi ^a   Shin, Kogyoku ^a   Murata Tai, Kaoru ^a   Fujisawa, Masae ^a   Ino, Mitsuhiro ^a   Shibata, Hisashi ^a   Yonaga, Masahiro ^a  

^a EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; N (CYCLOPROPYLMETHYL) 7 [2,6 DIMETHOXY 4 (METHOXYMETHYL)PHENYL] 2 ETHYL N [(TETRAHYDRO 2H PYRAN 4 YL)METHYL]PYRAZOLO[1,5 A]PYRIDIN 3 AMINE 4 METHYLBENZENESULFONATE; PYRAZOLE DERIVATIVE; PYRAZOLO[1,5 A]PYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; STRESS; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL AVAILABILITY; CYCLIC AMP; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; PYRAZOLES; PYRIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862300235     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300259r     Document Type: Article

References (36)

1. Vale, W.; Spiess, J.; Rivier, C.; Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin Science 1981, 213, 1394-1397
2. Owens, M. J.; Nemeroff, C. B. Physiology and pharmacology of corticotropin-releasing factor Pharmacol. Rev. 1991, 43, 425-473
3. Spiess, J.; Dautzenberg, F. M.; Sydow, S.; Hauger, R. L.; Ruhmann, A.; Blank, T.; Radulovic, J. Molecular properties of the CRF Receptor Trends Endocrinol. Metab. 1998, 9, 140-145
4. 2γ receptor Mol. Endocrinol. 1998, 12, 1077-1085
5. Chen, R.; Lewis, K. A.; Perrin, M. H.; Vale, W. W. Expression cloning of a human corticotropin-releasing-factor receptor Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8967-8971
6. Perrin, M. H.; Grace, C. R.; Riek, R.; Vale, W. W. The Three-Dimensional Structure of the N-Terminal Domain of Corticotropin-Releasing Factor Receptors. Sushi Domains and the B1 Family of G Protein-Coupled Receptors Ann. N.Y. Acad. Sci. 2006, 1070, 105-119
7. Smith, G. W.; Aubry, J.-M.; Dellu, F.; Contrarino, A.; Bilezekijian, L. M.; Gold, L. H.; Chen, R.; archuk, Y.; Hauser, C.; Bentley, C. A.; Sawchenko, P. E.; Koob, G. F.; Vale, W.; Lee, K.-F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development Neuron 1998, 20, 1093-1102
8. Timpl, P.; Spanagel, R.; Sillabar, I.; Kresse, A.; Reul, J. M.; Stalla, G. K.; Blanquet, V.; Steckler, T.; Holsboer, F.; Wurst, W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin- releasing hormone receptor 1 Nat. Genet. 1998, 19, 162-166
9. Dunn, A. J.; Berridge, C. W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 1990, 15, 71-100
10. Nemeroff, C. B.; Widerlov, E.; Bissette, G.; Wallens, H.; Karlsson, I.; Eklund, K.; Kilts, C. D.; Loosen, P. T.; Vale, W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients Science 1984, 226, 1342-1344
11. Arborelius, L.; Owens, M. J.; Plotsky, P. M.; Nemeroff, C. B. The role of corticotropin-releasing factor in depression and anxiety disorders J. Endocrinol. 1999, 160, 1-12
12. Zorrilla, E. P.; Koob, G. F. Progress in corticotropin-releasing factor-1 antagonist development Drug Discovery Today 2010, 15, 371-383
13. 1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response Neuropsychopharmacology 2007, 32, 1941-1949
14. Heinrichs, S. C.; De Souza, E. B.; Schulteis, G.; Lapsansky, J. L.; Grigoriadis, D. E. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist Neuropsychopharmacology 2002, 27, 194-202
15. 1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to Stress J. Pharmacol. Exp. Ther. 2003, 304, 874-880
16. 1 receptor antagonist Eur. J. Pharmacol. 1997, 323, 21-26
17. Arborelius, L.; Skelton, K. H.; Thrivikraman, K. V.; Plotsky, P. M.; Schulz, D. W.; Owens, M. J. Chronic Administration of the Selective Corticotropin-Releasing Factor 1 Receptor Antagonist CP-154,526: Behavioral, Endocrine and Neurochemical Effects in the Rat J. Pharmacol. Exp. Ther. 2000, 294, 588-597
18. Schulz, D. W.; Mansbach, R. S.; Sprouse, J.; Braselton, J. P.; Collins, J.; Corman, M.; Dunaiskis, A.; Faraci, S.; chmidt, A. W.; Seeger, T.; Seymour, P.; Tingley, F. D.; Winston, E. N., III; Chen, Y.; Heym, J. CP-154526, a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10477-10482
19. Li, Y.-W.; Hill, G.; Wong, H.; Kelly, N.; Ward, K.; Pierdomenico, M.; Ren, S.; Gilligan, P.; Grossman, S.; Trainor, G.; aub, R.; McElroy, J.; Zaczek, R. Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolyic Efficacy J. Pharmacol. Exp. Ther. 2003, 305, 86-96
20. Chen, C.; Grigoriadis, D. E. NBI 30775 (R121919), an Orally Active Antagonist of the Corticotropin-releasing Factor (CRF) Type-1 Receptor for the Treatment of Anxiety and Depression Drug Dev. Res. 2005, 65, 216-226
21. Zobel, A. W.; Nickel, T.; Künzel, H. E.; Ackl, N.; Sonntag, A.; Ising, M.; Holsboer, F. Effects of high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J. Psychiatric Res. 2000, 34, 171-181
22. 1 antagonist) in the treatment of major depression Amer. J. Psychiatry 2008, 165, 617-620
23. Chen, C.; Wilcoxen, K. M.; Huang, C. Q.; Xie, Y.-F.; McCarthy, J. R.; Webb, T. R.; Zhu, Y.-F.; Saunders, J.; Liu, X.-J.; Chen, T.-K.; Bozigian, H.; Grigoriadis, D. E. Design of 2,5-dimethyl-3- (6-dimethyl-4-methylpyridin-3-yl)- 7-dipropylaminopyrazolo[1,5-a] pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists J. Med. Chem. 2004, 47, 4787-4798
24. Chen, Y. L.; Mansbach, R. S.; Winter, S. M.; Brooks, E.; Collins, J.; Corman, M. L.; Dunaiskis, A. R.; Faraci, W. S.; allaschun, R. J.; Schmidt, A.; Schultz, D. W. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3- d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist J. Med. Chem. 1997, 40, 1749-1754
25. 1 receptor antagonist J. Med. Chem. 2000, 43, 449-456
26. Chen, Y. L.; Braselton, J.; Forman, J.; Gallaschun, R. J.; Mansbach, R.; Schmidt, A. W.; Seeger, T. F.; Sprouse, J. F.; Tingley, F. D.; Winston, E., III; Schulz, D. W. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropinreleasing factor 1 receptor antagonists J. Med. Chem. 2008, 51, 1377-1384
27. Gilligan, P. J.; Robertson, D. W.; Zaczek, R. Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents J. Med. Chem. 2000, 43, 1641-1660
28. Tamura, Y.; Minamikawa, J.; Sumoto, K.; Fujii, S.; Ikeda, M. Synthesis and some properties of O-acyl and O-nitrophenylhydroxylamines J. Org. Chem. 1973, 38, 1239-1241
29. Tsuchiya, T.; Sashida, H.; Konoshita, A. Thermal Rearrangements of Cyclic Amine Ylides. III. Intramolecular Cyclization of 2-Ethynylpyridine N-Imides to 3-Azaindolizine Derivatives Chem. Pharm. Bull. 1983, 31, 4568-5572
30. Ochi, H.; Miyasaka, T.; Kanada, K.; Arakawa, K. Studies of Heterocyclic Compounds. VIII. Synthesis and Tautomerism of 2-Hydroxypyrazolo[1,5- a ]pyridine Bull. Chem. Soc. Jpn. 1976, 49, 1980-1984
31. Fujito, H.; Tominaga, Y.; Matsuda, Y.; Kobayashi, G. Reaction of Pyridinium and Isoquinolinium N -imines with Ketenethioacetals Heterocycles 1977, 6, 379-382
32. Chen, R.; Lewis, A. K.; Perrin, H. M; Vale, W. Expression cloning of a human corticotropin-releasing-factor receptor Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8967-8971
33. Stepan, A. F.; Karki, K.; McDonald, W. S.; Dorff, P. H.; Dutra, J. K.; DiRico, K. J.; Won, A.; Subramanyam, C.; Efremov, I. V.; O'Donnell, C. J.; Nolan, C. E; Becker, S. L.; Pustilnik, L. R.; Sneed, B.; Sun, H.; Lu, Y.; Robshaw, A. E.; Riddell, D.; O'Sullivan, T. J.; Sibley, E.; Capetta, S.; Atchison, K.; Hallgren, A. J.; Miller, E.; Wood, A.; Obach, R. S. Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors. J. Med. Chem. 2011, 54, 7772-7783
34. Sugaya, Y.; Yoshiba, T.; Kajima, T.; Ishihama, Y. Development of Solubility Screening Methods in Drug Discovery YAKUGAKU ZASSHI 2002, 122, 237-246
35. Okuyama, S.; Chaki, S.; Kawashima, N.; Suzuki, Y.; Ogawa, A.; Nakazato, A.; Kumagai, T.; Okubo, T.; Tomisawa, K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001 J. Pharm. Exp. Ther. 1999, 289, 926-935
36. Belzung, C.; Misslin, R.; Vogel, E. Behavioural effects of the benzodiazepine receptor partial agonist RO 16-6028 in mice Psychopharmacology 1989, 97, 388-391